SRPK1 and prostate carcinoma: Quantitative analysis of an independent prostate cancer progression TMA cohort (University of Calgary) of 98 patients showed that both Kif3b and SRPK1 display significantly higher expression levels in prostate cancer epithelium compared to benign hyperplasia epithelium (Fig. 6a, b).